NCT07187063View on ClinicalTrials.gov

Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder Cancer

NARecruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

January 1, 2029

Study Completion Date

January 1, 2029

Conditions
Non-muscle Invasive Bladder Cancer (NMIBC)
Interventions
DIAGNOSTIC_TEST

UroAmp Test (Convergent Genomics, Inc.)

Non-invasive genomic urine test that can reliably detect, monitor, and predict the risk of urothelial cancer or its recurrence, potentially before signs and symptoms develop or become detectable by historical standards of care.

Trial Locations (1)

01805

RECRUITING

Lahey Hospital and Medical Center, Burlington

Sponsors

Lead Sponsor

Lahey Clinic
All Listed Sponsors
lead

Lahey Clinic

OTHER

NCT07187063 - Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder Cancer | Biotech Hunter | Biotech Hunter